Navigation Links
UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
Date:1/3/2008

Athens, Ga. More than 23 million Americans age 12 or older need treatment for substance abuse and addiction, yet only a fraction less than 10 percent actually receive it. Worse, among those who do get treatment, very few have access to the treatments that are known to work.

We have treatments that work, and we have people who want treatment, said Paul Roman, University of Georgia Distinguished Research Professor of Sociology and director of UGAs Center for Research on Behavioral Health and Human Services Delivery, a component of the Institute for Behavioral Research (IBR).

The problem now is getting treatment providers to adopt new, promising practices so that substance abusers can get the best treatment available.

Roman and a team of researchers based in the IBR have been awarded multiple grants totaling $9 million from both federal and private sources to improve the quality of substance abuse treatment. Last fall, Roman was awarded a five-year $3.2 million grant from the National Institutes of Health (NIH) to study the diffusion, adoption and implementation of effective substance abuse treatment practices in a network of clinical treatment providers across the country. Co-investigators are research scientists Lori Ducharme, Aaron Johnson and Hannah Knudsen. This grant follows a five-year $2.85 million grant from NIH in 2006 to continue a 15-year study tracking organizational changes and development in the national substance abuse treatment system.

It is hard to overestimate the societal value, both in dollars and in quality of life, of identifying effective ways to disseminate research-based treatments. It is a source of pride for UGA that we have such a strong research group working in this area, said David Lee, UGA vice president for research.

The intellectual impact of Romans group over the past 15 years has been tremendous, said Steven Beach, director of the UGA Institute for Behavioral Research. It is critically important that we foster the dialogue between treatment providers and those providing innovative, cost-effective, treatment improvements and Romans work has done precisely that.

Roman has observed the evolution of alcohol abuse and drug addiction treatment for over 25 years. New validated treatments available in recent years include FDA-approved pharmacotherapies for the treatment of addiction, psychosocial counseling and behavioral therapies. However, as Romans research has uncovered, individual, organizational and systemic barriers can get in the way of delivering those treatments to substance abusers.

The platform for Romans latest grant was laid in 1999 when the National Institute on Drug Abuse (NIDA), a division of NIH, launched its Clinical Trials Network (CTN) with the goal of testing scientifically-sound treatment practices in treatment settings to determine whether these practices will work in the real world, and what, if any, modifications may be needed. Beginning in 2001, NIH added funding to Romans research program to examine the adoption of CTN-studied practices within the network of CTN providers and compare them to programs outside the CTN, including public-sector treatment programs where increasing numbers of patients seek treatment. Over 1,350 treatment centers are included in the study.

Complementing his NIH funded-research, Roman also has a $1.9 million grant to evaluate Advancing Recovery, an $11 million national program funded by The Robert Wood Johnson Foundation to improve the quality of addiction care by supporting partnerships between treatment provider organizations and states. States are both the largest purchaser of publicly funded treatment services and regulators and licensers of those services. The evaluators will study how these partnerships can reduce barriers to adoption of evidence-based practices, ranging from variability in staff experience and education to purchasing and regulatory practices and adoption of consistent standards across state agencies.

Other IBR investigators have been awarded funding for complementary projects. In 2005, Lori Ducharme received a two-year $400,000 grant to study the diffusion of two evidence-based practices tested in the CTN: use of buprenorphine, a new medication for opiate dependence, and a behavioral therapy known as motivational incentives. In 2006, Lillian Eby, psychology (in collaboration with the IBR team), received a five-year grant totaling $2.55 million to examine the roles of clinical supervisors in substance abuse treatment centers. Her work will provide insights into the role that mentoring plays in reducing the turnover rate in the treatment workforce. Also in 2006, Amanda Abraham, IBR, received a $160,000 post-doctoral fellowship to focus specifically on the processes of adoption and implementation of the medications designed to treat alcohol dependence.


'/>"/>

Contact: Terry Hastings
thasting@uga.edu
706-542-5941
University of Georgia
Source:Eurekalert

Related medicine news :

1. Researchers seek to make cavity-causing bacteria self-destruct
2. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
3. New research tools are too complex for easy answers, researchers say
4. In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
5. U of M researchers discover fast-acting cyanide antidote
6. SLU researchers show how to stop muscle weakness caused by myasthenia gravis
7. Researchers solve first structure of a key to intact DNA inheritance
8. McGill researchers report breakthrough in rapid malaria detection
9. Tufts researchers update their food guide pyramid for older adults
10. U of M researchers develop new online tool in fight against spread of HIV
11. Researchers train the immune system to deliver virus that destroys cancer in lab models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: